Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for transcriptional differences in a 'discovery cohort' (total n = 90) and then we use t-tests to assess the reliability of any identified transcriptional differences in a 'validation cohort' (total n = 35). The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used prospectively to aid clinical diagnosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949789 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091076 | PLOS |
J Psychiatry Neurosci
January 2025
From the Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China (Gong, Wang, Nie, Ma, Zhou, Deng, Xie, Lyu, Chen, Kang, Liu); the Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, China (Liu)
Background: Cortical morphometry is an intermediate phenotype that is closely related to the genetics and onset of major depressive disorder (MDD), and cortical morphometric networks are considered more relevant to disease mechanisms than brain regions. We sought to investigate changes in cortical morphometric networks in MDD and their relationship with genetic risk in healthy controls.
Methods: We recruited healthy controls and patients with MDD of Han Chinese descent.
Alzheimers Dement
December 2024
Duke University School of Medicine, Durham, NC, USA.
Background: Patients with Alzheimer's Disease (AD) frequently manifest comorbid neuropsychiatric symptoms (NPS) with depression and anxiety being most prevalent. Previously we identified shared genetic risk loci between AD and major depressive disorder (MDD). In another study, we constructed a polygenic risk score (PRS) based on MDD-GWAS data and demonstrated its performance in predicting depression onset in LOAD patients.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brunel University London, London, United Kingdom.
Background: Apathy and mood symptoms are increasingly recognised as clinical important aspects of prodromal dementia; both are associated with increased risk of dementia even in cognitively normal people. The clinical overlap between apathy and low mood poses a challenge in distinguishing between the two conditions. It is crucial to differentiate between depression and apathy, along with any underlying syndromes, to facilitate the development of targeted treatments.
View Article and Find Full Text PDFBackground: Although there is clear evidence that therapeutic drug monitoring (TDM) has beneficial effects for patients treated with tricyclic antidepressants, it is generally not recommended for second-generation antidepressants (SGA). However, it has been suggested that methodological shortcomings might influence the results in TDM studies with SGA.
Aim: A qualitative assessment of randomized controlled trials (RCTs) that specifically investigated drug concentration-effect relationships of SGA in patients with major depressive disorder (MDD) to analyze the potential benefit of TDM during treatment with these agents.
Front Public Health
January 2025
Department of Psychiatry, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Background: Individuals exposed to wildfires are at risk of developing adverse mental health conditions in the months following the event. Receiving supportive text interventions during and after a wildfire event can have a significant impact on reducing mental health conditions over time.
Objectives: The study aimed to assess the effectiveness of a supportive text message intervention service in reducing the severity and prevalence of psychological conditions 3 months following the 2023 wildfires in Alberta and Nova Scotia, two regions heavily affected by these natural disasters.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!